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Influenza A(H1N1)pdm09 viruses have been circulating throughout the world since the 2009 pandemic.
A/California/07/2009 (H1N1) virus was included in seasonal influenza vaccines for seven years altogether,
providing a great opportunity to analyse vaccine-induced immunity in relation to the postpandemic evo-
lution of the A(H1N1)pdm09 virus. Serum antibodies against various epidemic strains of influenza A
(H1N1)pdm09 viruses were measured among health care workers (HCWs) by haemagglutination inhibi-
tion and microneutralization tests before and after 2010 and 2012 seasonal influenza vaccinations. We
detected high responses of vaccine-induced neutralizing antibodies to six distinct genetic groups. Our
results indicate antigenic similarity between vaccine and circulating A(H1N1)pdm09 strains, and sub-
stantial vaccine-induced immunity against circulating epidemic viruses.
 2019 Published by Elsevier Ltd.1. Introduction
Since the 2009 pandemic, influenza A(H1N1)pdm09 viruses
have been circulating throughout the world, evolving continuously
[1,2]. To date, eight genetic groups and several subgroups have
been identified in A(H1N1)pdm09 viruses [3]. Analyses using pan-
els of post-infection ferret antisera showed A(H1N1)pdm09 viruses
to be antigenically similar for relatively long time periods. There-
fore, A/California/7/2009 vaccine virus was recommended as the
seasonal influenza vaccine A(H1N1) strain for the Northern hemi-
sphere until the epidemic season 2016–2017 [4].
The haemagglutination inhibition (HI) test is the most com-
monly used method for measuring antibody levels against influ-
enza viruses, while the microneutralization (MN) test, which is
also widely employed, has certain advantages over the HI test
[5]. Measurable anti-influenza antibodies detected by the HI test
have been shown to correlate well with protective immunity [6].
In general, HI and MN antibody titres correlate [7], although the
MN assays appear to have a greater sensitivity [8–10]. Goodcorrelation has been shown between the results of different MN
assays [11], yet the ELISA-based neutralization assays tend to show
lower variation [12].
There has been a great deal of research on the immunogenicity
of the A(H1N1)pdm09 vaccine virus, which has mostly concen-
trated on analysing immune responses against the vaccine virus
itself [13–24]. However, limited amount of data is available on
vaccine-induced neutralizing antibody responses towards a wider
range of wild type epidemic A(H1N1)pdm09 viruses. For the pre-
sent study we collected sera from health care workers (HCWs)
before and after influenza vaccinations in 2010 and 2012. In the
present study we analysed vaccine-induced humoral immune
responses by HI and MN tests against viruses belonging to six
genetic subgroups of influenza A(H1N1)pdm09 virus. In addition,
we analysed the differences in immune responses induced by
two different vaccine preparations.
2. Materials and methods
2.1. Vaccines
The seasonal influenza vaccines administered in this study were
FluarixTM (GlaxoSmithKlein, lot number AFLUA523AA) in 2010 andtibody
2 A. Haveri et al. / Vaccine xxx (xxxx) xxxVaxigrip (Sanofi Pasteur MSD, lot numbers J8389-2 and J8395-2)
in 2012. Both vaccines were non-adjuvanted and contained the
three WHO-recommended influenza virus strains. The participants
were vaccinated in a national vaccination campaign. Different vac-
cines were used in different years due to a government funded
National Vaccination Programme that provided seasonal influenza
vaccines free to health care workers, young children, elderly and
medical risk groups according to national vaccination policy. Vac-
cines were administered intramuscularly (deltoid muscle) and
one vaccine dose was given to each person. Serum samples were
collected prior to vaccination on day 0, and the postvaccination
serum specimens were collected on day 21.
2.2. Participants
Clinically healthy HCWs were recruited on a voluntary basis
from the staff of the Department of Medicine at Helsinki Univer-
sity Hospital and the Virology Unit at the National Institute for
Health and Welfare. Eight men and 42 women, median age
47 years (range: 19–64), were involved in the FluarixTM vaccina-
tion trial in 2010. Two years later, at the time of the Vaxigrip
vaccination in 2012, eight men and 42 women, median age
46 years (range: 24–65), participated in the study. 23 of the par-
ticipants were included in both vaccination studies. All partici-
pants gave their informed written consent before enrolment in
the study.
2.3. Viruses
Representative viruses from six genetic groups of influenza A
(H1N1)pdm09 viruses that circulated in Finland during 2009–
2013 [25,26] were selected for serological analyses: A/Finland/
554/2009 (group 1), A/Finland/24/2010 (group 3), A/Finland/124/
2011 (group 4), A/Finland/153/2011 (group 5), A/Finland/148/2011
(group 7), A/Finland/142/2011 (group 6A), A/Finland/300/2012
(group 7), A/Finland/308/2013 (group 6C). Additionally, the
A/California/07/2009 (group 1) vaccine virus was included in the
analyses. The clinical samples for isolation of the viruses included
in this study have been collected for routine viral diagnostic pur-
poses. Based on national laws, ethical permission was not required
for specific microbiological diagnostics and further characterisa-
tion of detected viruses. All viruses were propagated in MDCK cells
and stored in aliquots at 70 C.
2.4. Phylogenetic and structural analyses of the HA molecule
The phylogenetic analysis of the HA gene for selected Finnish
viruses and reference strains was performed as described [25].
Mega (Molecular Evolutionary Genetics Analysis) software ver-
sion 5 [27] was used in amino acid sequence comparison and
the construction of the phylogenetic tree. The Neighbour-joining
method [28] with the maximum composite likelihood model
[29] was used to generate the phylogenetic tree. Bootstrapping
was performed with 1000 replicates [30]. Reference virus
sequences for the phylogenetic tree were obtained from GISAID
EpiFluTMDatabase.
The three-dimensional structure of the HA molecule of the
influenza A(H1N1)pdm09 virus, A/California/04/2009 (RCSB Pro-
tein Bank accession number 3LZG) was used to locate amino acid
differences between the epidemic Finnish A(H1N1)pdm09 viruses
(seasons 2009–2010, 2010–2011 and 2012–2013) and the A/Cali-
fornia/07/2009 vaccine virus. The molecular models were con-
structed using RasMol Molecular Graphics software version 2.7.3
[31]. Amino acid residues in the HA molecule were numbered
without the signal peptide sequence.Please cite this article as: A. Haveri, N. Ikonen, A. Kantele et al., Seasonal influ
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Antibody levels were measured in serum specimens collected
before the vaccination (day 0) and 21 days after the vaccination
with seasonal influenza vaccines Fluarix (2010) or Vaxigrip (2012).
Serum specimens were assayed by the haemagglutination inhi-
bition (HI) test against the virus strains described above. The HI
tests were performed according to WHO guidelines [32] using tur-
key erythrocytes (0.5%/vol). For statistical analyses, serum speci-
mens with HI titers <10 were assigned a titer value of 5.
Microneutralization (MN) tests were performed with the virus
strains described above (excluding A/Finland/554/2009 due to
low amounts of serum specimens). The MN test was done accord-
ing to the WHO guidelines [32]. We optimized the MN tests for the
particular viruses and antibodies used in this study.
In the MN test two-fold serial dilutions of heat inactivated sera
were performed in 50 ml volumes of the diluent (OptiProTM SFM,
Gibco, supplemented with 0.2% BSA, non-essential amino acids
and Penicillin-Streptomycin) in 96-well tissue culture plates.
Serum dilutions were mixed with diluent containing 100 TCID50
of different influenza viruses. Control wells with the virus and
the diluent (VC), the diluent alone (CC) and an internal positive
control were included in each plate. After incubation for 1 h at
37 C with 5% CO2, 2.5  104 MDCK cells were added to each well
for an 18–20 h incubation at 37 C with 5% CO2. Wells were fixed
within cold 80% acetone for 10 min.
The presence of influenza antigens in fixed cells was detected
by enzyme-linked immunosorbent assay (ELISA). The fixed plates
were washed with washing buffer (PBS, 0.05% Tween 20). An in-
house rabbit antibody against the whole virus (A/Califor-
nia/07/2009 whole virion vaccine antigen, GSK) [26] was used as
the primary antibody. The antibody was diluted 1:4000 in PBS con-
taining 5% milk. 80 ml of antibody dilution was added and incu-
bated at room temperature for 1 h followed by washing with
washing buffer (see above). Subsequently, 80 ml of 1:2000 dilution
of polyclonal horseradish peroxidase-labeled goat anti-rabbit
immunoglobulins (Dako, Denmark) was added to each well and
incubated at room temperature for 1 h followed by washing as
above. Freshly prepared substrate o-phenylenediamine dihy-
drochloride (100 ml) (Sigma-Aldrich, USA) was added into each
well and incubated at room temperature. The reaction was stopped
after 20 min with 100 ml 1 M sulfuric acid. Absorbances were mea-
sured at 492 nm and 620 nm. The neutralizing endpoint was deter-
mined as previously described [32]. For statistical analyses, serum
specimens with MN titers < 10 and greater than 1280 were
assigned a titer value of 5 and 2560, respectively.2.6. Statistical analysis
Geometric mean titers (GMT) with 95% confidence intervals and
seroprotection rates (HI titer  1:40, MN titer  1:160) for each
virus were calculated. Statistical differences between the groups
were calculated using Student’s t-test (paired, two-tailed) and
the statistically significance level of difference was set to p < 0.01.
HI and MN assays were correlated and compared with Pearson
and t-tests. Log-transformed titers were performed by linear
regression analysis using Microsoft Excel 2010 software.3. Results
The epidemic A(H1N1)pdm09 viruses used in this study were
collected between the years 2009 and 2013 from sentinel sites of
influenza surveillance network (garrisons and health care centres
for general public) and non-sentinel sites (clinical microbiology
laboratories) situating in different geographic regions in Finland.enza vaccines induced high levels of neutralizing cross-reactive antibody
accine, https://doi.org/10.1016/j.vaccine.2019.03.078
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number of amino acid substitutions increased during the evolution
of the HA gene (Table 1) and the changes occurring on the surface
of the HA molecule compared to the A/California/07/2009 virus
(vaccine virus) are illustrated in Fig. 2.
Using vaccine virus A/California/07/2009 as a reference strain,
we found that the antibody titers of the HI and MN assays corre-
lated strongly positively (n = 190, r = 0.6287, R2 = 0.8215,
p < 0.0001). A HI titer of 40 was considered to be equivalent to a
MN titer of 160 (Fig. 3).
Geometric mean titers (GMTs) obtained with the MN test were
typically higher than those seen in the HI test (Table 2). Pre-
existing A(H1N1)pdm09 antibody titres did not differ statistically
significantly between the groups of 2010 and 2012. Three weeks
after Fluarix and Vaxigrip vaccinations, GMTs for both assays and
for all studied viruses increased significantly p < 0.01 –
p < 0.0001, respectively.
Vaccine-induced anti-H1N1pdm09 antibody GMTs were
somewhat higher after administration of the Fluarix vaccineFig. 1. Phylogenetic tree of the haemagglutinin (HA) sequences of influenza A(H1N1)pdm
were 1698 nucleotides long. The tree was constructed by the neighbour-joining method w
in bold type. Reference strains are included for comparison. The horizontal lines are propo
numbers.
Table 1
Evolutionary changes of the haemagglutinin (HA) gene. The number of amino acid chang
vaccine strain A/California/07/2009.
Virus strain Genetic
group
Number of
changes
Antigenic sites
Sa Sb C
A/California/07/2009 1
A/Finland/554/2009 1 3
A/Finland/24/2010 3 6
A/Finland/124/2011 4 5 N125D
A/Finland/153/2011 5 8
A/Finland/148/2011 7 8 S185T
A/Finland/142/2011 6A 9 S185T
A/Finland/300/2012 7 11 K160N* S185T
A/Finland/308/2013 6C 13 S185T,
A186T
T
* Potential glycosylation site NLS (160–162).
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(Table 2). As analysed by the HI test Fluarix vaccine induced
antibody responses between the prevaccine and postvaccine
serum specimens increased 3.2 to 5.4-fold depending on the
virus strain. In the Vaxigrip group the corresponding increases
were 2.0 to 2.5-fold for different viruses (Fig. 2a). The GMTs
for Fluarix and Vaxigrip vaccine induced antibody rises mea-
sured by the MN test ranged from 4.9 to 7.4 and from 2.4 to
2.8, respectively (Fig. 2b). It is noteworthy that the basal levels
(day 0) of anti-H1N1pdm09 antibodies were somewhat higher
in the Vaxigrip vaccine group and thus the fold increase
remained at a lower level as compared to that seen in the Flu-
arix group. However, in all cases the postvaccination (day 21)
GMTs were higher in the Fluarix group as compared to the Vax-
igrip group (Fig. 2a and b).
Next we analyzed the rate of seroprotection i.e. the percent-
age of individuals showing 1:40 titer in the HI test and
1:160 titer in the MN test, before and after influenza vaccina-
tion. Seroprotection rates (SRs) as measured by HI and MN tests,09 viruses. The strains were identified in Finland during 2009–2013; all sequences
ith Mega software version 5.1. The viruses used in serological tests are highlighted
rtional to the number of nucleotide changes. Different genetic groups are marked as
es between the HA of Finnish pandemic viruses used in this study compared to the
Other sites
b Ca1 Ca2
P83S, I321V, S451N
S203T P83S, A134T, S183P, I321V, N441K
S203T P83S, I321V, E374K
S203T,
R205K
P83S, D97N, I216V, V249L, I321V, E274K
S203T P83S, S143G, A197T, I321V, E374K, S451N
S203T N56S, P83S, D97N, I321V, E356G, E374K, S451N
S203T P83S, A197T, I216M, I321V, E374K, S451N, I460T,
E499K
72A S203T P83S, D97N, V173I, V234I, K283E, I321V, E374K,
S451N, E499K
enza vaccines induced high levels of neutralizing cross-reactive antibody
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Fig. 2. Schematic representation of amino acid differences in the HA molecule between the Finnish influenza A(H1N1)pdm09 viruses and the vaccine virus, A/California/07/
2009. On the upper left, a side view of the monomeric structure of HA molecule of influenza A(H1N1)pdm09 (A/California/04/2009; RCSB Protein Bank accession number
3LZG) with previously identified H1 protein-specific antigenic sites (Sa in red, Sb in blue, Ca1 in darker green, Ca2 in lighter green and Cb in orange) of influenza A(H1N1)
viruses and with the receptor binding pocket (RBP, purple) is shown. The amino acid changes in Finnish A(H1N1)pdm09 viruses compared to A/California/07/2009, the
vaccine strain, are illustrated in the monomeric HA structure and coloured as in the A/California/07/2009 structure. Amino acid changes outside the antigenic sites are shown
in yellow. Changes are illustrated by amino acid residue numbers and with a serial number of the virus where the respective amino acid change has been observed. * potential
glycosylation site NLS (160–162). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Correlation of the antibody titres to A/California/07/2009 measured by
haemagglutination inhibition (HI) and microneutralization (MN) tests. Log-trans-
formed HI and MN titres are presented, trend line and coefficient of determination
calculated by linear regression analysis. Each dot may include the value from
several serum specimens. Total number of serum specimens is 190.
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responses against different genetic group influenza A(H1N1)pdm09 viruses, Vwere almost equally high in both vaccine groups and both
vaccines induced SRs that were well over 70% that is considered
as the rate for an efficient vaccination. However, somewhat
higher SR values were obtained by the MN test (Fig. 4). Pre-
existing SR values were higher in 2012 compared to those seen
in the 2010 vaccine group. SRs before 2010 and 2012 vaccina-
tions varied 32.7–49.0% and 30.0–64.0% in the HI test and
34.0–52.0% and 44.0–56.0% in the MN test, respectively. Both
vaccinations induced very high SRs. HI SRs ranged from 75.5–
89.8% to 74.0–84.0% and MN SRs ranged from 82.0–94.0% to
78.0–86.0% for different virus strains after Fluarix 2010 and Vax-
igrip 2012 vaccinations, respectively.
Correlation coefficients (r) of antibody levels between A/Califor-
nia/07/2009 vaccine virus and epidemic A(H1N1)pdm09 viruses
are shown in Table 3. Significant correlation (p < 0.0001) between
all virus strains was seen. There was, logically, a tendency for the
correlation coefficient to be higher between the viruses that were
genetically and structurally more closely related with the vaccine
virus and each other. Correlation of A/California/07/2009 and
selected epidemic strain-specific antibody responses are shown
(Fig. 5).enza vaccines induced high levels of neutralizing cross-reactive antibody
accine, https://doi.org/10.1016/j.vaccine.2019.03.078
Table 2a
Vaccine-induced humoral immune responses against different influenza A(H1N1)pdm09 viral strains measured by haemagglutination inhibition (HI) test.
Virus strain (genetic group) A/California/
07/2009 (1)
A/Finland/
554/2009 (1)
A/Finland/
24/2010 (3)
A/Finland/
124/2011 (4)
A/Finland/
153/2011 (5)
A/Finland/
142/2011
(6A)
A/Finland/
308/2013
(6C)
A/Finland/
148/2011 (7)
A/Finland/
300/2012 (7)
Geometric mean titer [95% Cl]
Fluarix vaccine 2010#
Day 0 (n = 49) 30.1
[20.4–44.4]
22.1
[14.8–32.9]
20.3
[14.2–28.9]
20.0
[14.3–28.0]
26.5
[18.4–38.3]
19.4
[13.9–27.3]
22.4
[15.7–31.9]
23.4
[16.6–32.9]
33.3
[23.0–48.1]
Day 21 (n = 46–49) 162.4***
[110.2–239.5]
116.6***
[79.2–171.6]
74.5***
[55.7–99.8]
81.1***
[59.9–109.9]
112.3***
[83.9–150.4]
62.9***
[47.1–84.1]
73.5***
[53.1–101.8]
87.1***
[66.8–113.5]
135.0***
[98.7–184.7]
Fold increase 5.4 5.3 3.7 4.1 4.2 3.2 3.3 3.7 4.1
Vaxigrip vaccine 2012a
Day 0 (n = 50) 35.8
[25.9–49.5]
27.9
[20.0–38.9]
23.0
[17.1–30.9]
24.3
[17.9–32.9]
32.5
[24.0–43.9]
21.1
[15.9–28.2]
24.6
[18.5–32.9]
30.7
[22.8–41.5]
36.8
[26.7–50.8]
Day 21 (n = 50) 81.1**
[60.0–109.7]
66.0**
[48.9–88.8]
54.3***
[41.6–70.8]
55.0**
[41.3–73.2]
80.0***
[60.5–105.8]
46.6**
[35.0–62.0]
48.6*
[37.1–63.6]
67.7**
[51.3–89.5]
85.7**
[65.1–112.9]
Fold increase 2.3 2.4 2.4 2.3 2.5 2.2 2.0 2.2 2.3
The significance of differences (increase) between day 0 and day 21 geometric mean titres *p < 0.01 **p < 0.001 ***p < 0.0001.
# One dose of non-adjuvanted trivalent seasonal influenza vaccine Fluarix produced by GSK Biologicals was given in 2010.
a One dose of non-adjuvanted trivalent seasonal influenza vaccine Vaxigrip produced by Sanofi Pasteur was given in 2012.
Table 2b
Vaccine-induced humoral immune responses against different influenza A(H1N1)pdm09 viral strains measured by microneutralization (MN) test.
Virus strain
(genetic group)
A/California/07/
2009 (1)
A/Finland/24/
2010 (3)
A/Finland/124/
2011 (4)
A/Finland/153/
2011 (5)
A/Finland/142/
2011 (6A)
A/Finland/308/
2013 (6C)
A/Finland/148/
2011 (7)
A/Finland/300/
2012 (7)
Geometric mean titer [95% Cl]
Fluarix vaccine 2010#
Day 0 (n = 50) 94.5
[60.5–147.5]
82.2
[48.7–138.7]
86.9
[55.9–135.3]
83.4
[51.8–134.2]
113.1
[67.6–189.4]
85.7
[53.4–137.5]
139.3
[91.2–212.7]
107.0
[67.0–171.1]
Day 21 (n = 50) 667.2***
[472.1–942.9]
498.7***
[343.8–723.2]
622.5***
[439.0–882.7]
613.9***
[435.4–865.7]
735.2***
[531.3–1017.2]
434.1***
[312.2–603.7]
676.5***
[483.5–946.4]
631.2***
[446.5–892.2]
Fold increase 7.1 6.1 7.2 7.4 6.5 5.1 4.9 5.9
Vaxigrip vaccine 2012a
Day 0 (n = 50) 130.0
[86.3–195.7]
108.5
[69.7–169.0]
130.0
[86.0–196.4]
130.0
[87.8–192.4]
145.2
[94.2–223.7]
97.1
[65.5–144.0]
145.2
[99.9–211.1]
137.4
[91.6–206.1]
Day 21 (n = 50) 315.6*
[226.3–440.2]
307.0**
[216.3–435.7]
338.2**
[239.1–478.5]
333.6**
[238.7–466.3]
388.5**
[273.4–552.2]
229.4*
[167.7–313.9]
343.0**
[251.9–467.0]
343.0**
[249.5–471.5]
Fold increase 2.4 2.8 2.6 2.6 2.7 2.4 2.4 2.5
The significance of differences (increase) between day 0 and day 21 geometric mean titres *p < 0.01 **p < 0.001 ***p < 0.0001.
# One dose of non-adjuvanted trivalent seasonal influenza vaccine Fluarix produced by GSK Biologicals was given in 2010.
a One dose of non-adjuvanted trivalent seasonal influenza vaccine Vaxigrip produced by Sanofi Pasteur was given in 2012.
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The first influenza pandemic of the 21st century was caused by
a novel reassortant H1N1 swine influenza virus with gene seg-
ments originating from avian, human and swine viruses [33]. Since
the 2009 pandemic, influenza A(H1N1)pdm09 strains have contin-
ued to circulate in humans causing seasonal influenza epidemics. A
(H1N1)pdm09 viruses have also succeeded in crossing the species
barrier, and novel reassortant viruses with internal genes of A
(H1N1)pdm09 found in pigs may pose a threat to public health
[34].
Antigenic sites of the HA molecule in H1N1 viruses have been
identified which include the epitopes Sa, Sb, Ca1, Ca2 and Cb on
the surface of the globular head of the molecule (Fig. 2) [35,36].
During the evolution, A(H1N1)pdm09 viruses have carried more
HA point mutations in the stem region than in antigenic sites [1].
A substitution E224A and others located in or in the vicinity of
amino acid 151–159 surface loop have caused antigenic changes
that can be detected in HI assays [37]. Reduced HI titres were also
reported with amino acid changes N125D and N156K in the Sa epi-
tope [26]. The yearly mutation rate at amino acid level has been
estimated to be approximately 1.5% for the HA1 and 1.1% for the
NA molecule [25].
The A(H1N1) viral component (A/California/07/2009) of sea-
sonal influenza vaccines remained the same for several years, fromPlease cite this article as: A. Haveri, N. Ikonen, A. Kantele et al., Seasonal influ
responses against different genetic group influenza A(H1N1)pdm09 viruses, Va2010–2011 to 2016–2017, which enabled us to compare the
immunogenicity of different vaccine preparations as well as to
analyse the cross-reactivity of seasonal influenza vaccine-induced
immunity against a wide variety of epidemic A(H1N1)pdm09 virus
strains. We also compared the performance of the traditional HI
assay and optimized the ELISA-based MN test analyzing vaccine-
induced responses. In general, the levels of anti-influenza antibod-
ies detected by the HI and MN assays correlated very well with
each other, strongly suggesting that both assays measure similar
types of anti-influenza antibodies. In other studies a good correla-
tion has been shown between HI and MN assays, and also high sen-
sitivity and specificity of MN for A/California/07/2009 vaccine virus
induced antibody responses [38].
In accordance with previous observations [5], we found that MN
titres tend to be higher than those obtained in the HI test. The HI
titre of 40 corresponded to a MN titre of 160. However, the data
on the protective value of MN antibody titres against influenza var-
ies considerably depending on the method and viruses used in the
assays [8,9,39].
The GMTs elicited by the 2010 Fluarix vaccination appeared to
be higher than those seen after the 2012 Vaxigrip vaccination. The
comparison of vaccine-induced antibody levels is difficult, since
the vaccines were given in separate clinical trials. Moreover, the
immune status of the vaccinees differed to some extent when
the vaccines were administered in 2010 and 2012. Most of the par-enza vaccines induced high levels of neutralizing cross-reactive antibody
ccine, https://doi.org/10.1016/j.vaccine.2019.03.078
Fig. 4. Seroprotection rates determined by (a) hemagglutination inhibition test (HI) and (b) microneutralization test (MN) before and after vaccination of 50 health care
workers with trivalent influenza vaccine Fluarix in 2010 or Vaxigrip in 2012. The seroprotection rate was defined as the percentage of participants with a titre of 40 and
160 for HI and MN tests, respectively. The striped columns indicate seroprotection rates before vaccination (day 0) and solid grey columns indicate seroprotection rates at
three weeks after vaccination (day 21). nd: not done (due to reduced amount of sera).
Table 3
Correlation coefficiencies of the antibody titres between different A(H1N1)pdm09 virus isolates used in (a) haemagglutination inhibition (HI) test and (b) microneutralization
(MN) test. The Pearson correlation coefficiencies (r) were calculated and all values were highly significant (p < 0.0001). nd: not done.
A
Genetic group 1 3 4 5 6A 6C 7 7
Virus strain 554/09 24/10 124/11 153/11 142/11 308/13 148/11 300/12
A/California/7/2009 0.88 0.71 0.74 0.74 0.71 0.63 0.68 0.70
A/Finland/554/2009 0.76 0.85 0.78 0.78 0.68 0.76 0.71
A/Finland/24/2010 0.80 0.91 0.98 0.71 0.94 0.85
A/Finland/124/2011 0.87 0.82 0.86 0.83 0.87
A/Finland/153/2011 0.91 0.82 0.93 0.92
A/Finland/142/2011 0.69 0.95 0.84
A/Finland/308/2013 0.72 0.83
A/Finland/148/2011 0.84
A/Finland/300/2012
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Table 3 (continued)
B
Genetic group 1 3 4 5 6A 6C 7 7
Virus strain 554/09 24/10 124/11 153/11 142/11 308/13 148/11 300/12
A/California/7/2009 nd 0.86 0.81 0.86 0.88 0.84 0.88 0.89
A/Finland/554/2009 nd nd nd nd nd nd nd
A/Finland/24/2010 0.67 0.86 0.84 0.84 0.85 0.88
A/Finland/124/2011 0.78 0.85 0.71 0.78 0.78
A/Finland/153/2011 0.89 0.86 0.91 0.91
A/Finland/142/2011 0.81 0.87 0.88
A/Finland/308/2013 0.86 0.87
A/Finland/148/2011 0.96
A/Finland/300/2012
HI test MN test
Fig. 5. Correlation of A/California/07/2009 and selected epidemic strain-specific antibody responses. Each dot may include the value from several serum specimens; their
number totals 190–200 in each panel.
A. Haveri et al. / Vaccine xxx (xxxx) xxx 7ticipants in the Fluarix trial in 2010 had been given the vaccine
Pandemrix only one year before the seasonal vaccination. Previous
Pandemrix vaccination has been shown to strongly boost antibody
responses against A(H1N1)pdm09 viruses [40].
A total of 23 volunteers were the same in 2010 and 2012 trials,
thus their immunization history was not similar during the twoPlease cite this article as: A. Haveri, N. Ikonen, A. Kantele et al., Seasonal influ
responses against different genetic group influenza A(H1N1)pdm09 viruses, Vatime periods: in 2012 most of the volunteers had an additional his-
tory of receiving vaccinations in 2010 and 2011. Indeed, albeit not
statistically significant, we saw a tendency of somewhat higher
pre-existing anti-H1N1pdm09 antibody levels and higher seropro-
tection rates in 2012 than in 2010. This may be due, not only to a
history of sequential vaccinations among the study population, butenza vaccines induced high levels of neutralizing cross-reactive antibody
ccine, https://doi.org/10.1016/j.vaccine.2019.03.078
8 A. Haveri et al. / Vaccine xxx (xxxx) xxxin some cases, also to natural infections caused by A(H1N1)pdm09
viruses. Three weeks after vaccination with either one of the vacci-
nes the GMT values increased significantly against all studied
viruses. No significant differences between different virus-
specific responses were found. Both seasonal influenza virus vacci-
nes induced adequately high antibody levels that showed very
good cross-reactivity against all analysed circulating wild type A
(H1N1)pdm09 virus from different genetic groups. Accordingly,
repeated annual vaccinations have been shown to be beneficial
to HCWs promoting antibody avidity maturation against A/
California/07/2009-like vaccine virus [13].
As measured by the MN test, correlation coefficiencies of the
antibody titres between the A/California/07/2009 vaccine virus
and epidemic A(H1N1)pdm09 viruses were somewhat higher as
compared to the results obtained by the HI test. As the MN assay
provides the detection of a wider range of antibodies than the HI
test, the MN test is likely more sensitive in identifying antigenic
similarities or differences between the viruses [5]. Although MN
test is more laborious to conduct than the HI test, the MN test
offers greater specificity, sensitivity and probably also better corre-
lation to protection. Therefore, it should be favored in analyses of
vaccine (and infection)-induced anti-influenza immunity. Pre-
sently, the HI assay fails to efficiently characterize A(H3N2) viruses
due to either the variable agglutination of red blood cells from gui-
nea pig, turkey and humans or the loss of the ability of viruses to
agglutinate any of these cells [41]. The MN test may also be a more
reliable method than the HI test in analysing vaccine- or natural
infection-induced immunity against influenza viruses of various
types, including the recently emerged H3N2 viruses.
Within a potential N-linked glycosylation site (160–162), the
substitution K160N located in the antigenic site Sa of the A/Fin-
land/300/2012 strain did not changed the antigenic profile com-
pared to the A/California/07/2009 vaccine virus. Albeit we saw
only limited antigenic variation in the responses against different
genetic group viruses there was a tendency for the correlation
coefficient to be higher between the viruses that were genetically
and structurally more closely related to the vaccine virus and to
each other.
In Finland, influenza A(H1N1)pdm09 viruses predominated
during the influenza seasons 2009–2010 [42], 2012–2013,
2013–2014 and 2015–2016 [43–45]. Our results indicate that the
A/California/07/2009 vaccine virus induced antibodies with high
cross-reactive potential, which likely provided good cross-
protection against epidemic A(H1N1)pdm09 viruses during the
influenza seasons 2010–2011 and 2012–2013. We have also shown
that the A/California/07/2009 vaccine induced high seroprotection
rates against a Finnish epidemic genetic group 6B virus that was
isolated in 2014 [46].
During the influenza season 2015–2016 two sub-clades within
the 6B clade emerged: 6B.1 and 6B.2. HI and virus neutralization
assays using ferret antisera indicated that almost all the A(H1N1)
pdm09 viruses were antigenically similar and closely related to
the vaccine virus A/California/07/2009 [4]. The A/Califor-
nia/07/2009 vaccine strain was changed to A/Michigan/45/2015
and A/Brisbane/02/2018 strains for the 2017 southern and 2019–
2020 northern hemisphere vaccines, respectively [47,48]. Both
changes were based on immunogenicity analyses in humans rather
than experimental data obtained in ferrets. HI assays with ferret
antisera indicated that almost all recent A(H1N1)pdm09 viruses
were antigenically indistinguishable from the vaccine virus yet
some of the epidemic viruses were poorly inhibited by some
post-vaccination human sera.
Our study has certain limitations. As the number of HCWs par-
ticipating was no larger than 50 and all age groups were not cov-
ered, the results do not necessarily apply to children or elderly
individuals. Vaccine effectiveness in general remains lower amongPlease cite this article as: A. Haveri, N. Ikonen, A. Kantele et al., Seasonal influ
responses against different genetic group influenza A(H1N1)pdm09 viruses, Vthe elderly than among children and adults [49]. The results
obtained in the two vaccination trials are not comparable as such,
since the vaccines were not administered during the same year and
the immune history of the vaccinees were likely quite different.
Indeed, it is desirable that future studies would not only explore
responses to the vaccine strains but would also compare different
(seasonal) influenza vaccines for their immunogenicity and protec-
tive efficacy in the same clinical trial. However, it should be
pointed out that both vaccines induced strong homologous and
heterologous antibody responses against multiple A(H1N1)
pdm09 viruses with very high theoretical seroprotection rates.
In the present study we optimized and used an MN assay
together with a traditional HI assay to investigate antibody levels
after seasonal influenza virus vaccinations. We demonstrated high
rates of neutralizing antibodies against different circulating genetic
groups of influenza A(H1N1)pdm09 viruses three weeks after
seasonal influenza vaccinations. The results suggest strong
vaccine-induced protection against circulating A(H1N1)pdm09
viruses isolated in Finland between the years 2009 and 2013. In
addition to protecting the staff themselves against influenza,
vaccination of HCWs fulfills an important task of preventing the
spread of influenza among the vulnerable patient groups.Acknowledgements
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